- Home
- FLG vs GRFS Comparison
FLG vs GRFS Comparison
Compare FLG & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLG
- GRFS
- Stock Information
- Founded
- FLG 1859
- GRFS 1940
- Country
- FLG United States
- GRFS Spain
- Employees
- FLG N/A
- GRFS 23737
- Industry
- FLG
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- FLG
- GRFS Health Care
- Exchange
- FLG NYSE
- GRFS Nasdaq
- Market Cap
- FLG 4.9B
- GRFS 5.5B
- IPO Year
- FLG 1993
- GRFS 2006
- Fundamental
- Price
- FLG $10.01
- GRFS $8.05
- Analyst Decision
- FLG Hold
- GRFS Sell
- Analyst Count
- FLG 4
- GRFS 2
- Target Price
- FLG $12.13
- GRFS $10.50
- AVG Volume (30 Days)
- FLG 5.2M
- GRFS 1.3M
- Earning Date
- FLG 11-08-2024
- GRFS 01-01-0001
- Dividend Yield
- FLG 0.40%
- GRFS N/A
- EPS Growth
- FLG N/A
- GRFS N/A
- EPS
- FLG N/A
- GRFS 0.27
- Revenue
- FLG $1,427,000,000.00
- GRFS $7,814,096,584.00
- Revenue This Year
- FLG N/A
- GRFS $8.86
- Revenue Next Year
- FLG N/A
- GRFS $7.00
- P/E Ratio
- FLG N/A
- GRFS $35.12
- Revenue Growth
- FLG N/A
- GRFS 7.21
- 52 Week Low
- FLG $5.10
- GRFS $5.30
- 52 Week High
- FLG $31.95
- GRFS $12.15
- Technical
- Relative Strength Index (RSI)
- FLG N/A
- GRFS 51.40
- Support Level
- FLG N/A
- GRFS $7.29
- Resistance Level
- FLG N/A
- GRFS $7.85
- Average True Range (ATR)
- FLG 0.00
- GRFS 0.33
- MACD
- FLG 0.00
- GRFS 0.06
- Stochastic Oscillator
- FLG 0.00
- GRFS 77.22
About FLG FLAGSTAR FINANCIAL INC
Flagstar Financial Inc operates over 400 branches, including a presence in the Northeast and Midwest and locations in high-growth markets in the Southeast and West Coast. In addition, the Bank has approximately 90 private banking teams located in over 10 cities in the metropolitan New York City region and on the West Coast, which serve the needs of high net-worth individuals and their businesses.
About GRFS Grifols S.A.
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.